Evidence map›Paper›PMID 42043587›Full record

ArticleAnnals of hematology2026

Differential impact of allogeneic stem-cell transplantation on large B-cell lymphomas and peripheral T-cell lymphomas.

Futoshi Yoshino, Daisuke Kaji, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Futoshi YoshinoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.
Daisuke KajiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan. kaji613@toranomon.gr.jp.
Mika KunoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.
Otoya WatanabeDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.
Kyosuke YamaguchiDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Kosei KageyamaDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Yuki TayaDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Aya NishidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.
Shinsuke TakagiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.
Hisashi YamamotoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.
Yuki Asano-MoriDepartment of Transfusion and Cellular Therapy, Toranomon Hospital, Tokyo, Japan.
Atsushi WakeDepartment of Hematology, Toranomon Hospital Kajigaya, Kawasaki, Japan.
Shuichi TaniguchiDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.
Naoyuki UchidaDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.
Go YamamotoDepartment of Hematology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 1058470, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is one of the standard treatments for relapsed/refractory (r/r) non-Hodgkin lymphoma, but benefits across large B-cell lymphoma (LBCL) and nodal peripheral T-cell lymphoma (PTCL) subtypes remain unclear. This single-center retrospective study evaluated outcomes after the first allo-HSCT in 92 adults with r/r aggressive lymphoma (59 and 33 patients with LBCLs and PTCLs, respectively) treated during 2011–2023. The patients’ median age was 51 years; 58.7% had active disease at transplant, and 77.2% received cord blood grafts. With a median follow-up of 7.6 years among survivors, the 5-year overall survival (OS) and progression-free survival (PFS) rates were 31.6% and 27.9%, respectively. Furthermore, the non-relapse mortality (NRM) and relapse/progression rates were 30.8% and 41.3%, respectively. Compared with patients with LBCLs, those with PTCLs showed superior 5-year outcomes (OS: 47.7% vs. 22.4%, P = 0.03; PFS: 39.7% vs. 21.0%, P = 0.04) and lower relapse rates (26.9% vs. 49.5%, P = 0.02), with similar NRM and acute graft-versus-host disease rates. Multivariable models showed that PTCL histology was an independent predictor of improved OS and PFS. These findings suggest that allo-HSCT confers greater long-term benefits in patients with PTCL, supporting its role as an effective option in this subgroup.

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Large B-Cell, DiffuseLymphoma, T-Cell, PeripheralAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedRetrospective StudiesSurvival RateTransplantation, HomologousAllogeneic stem cell transplantationCord blood transplantationLarge B-cell lymphomaNon-Hodgkin lymphomaPeripheral T-cell lymphoma

Identifiers

PMID42043587
PMCPMC13121212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.